Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022)
Edgewise Therapeutics (EWTX) posted Total Non-Current Liabilities of $10.9 million for Q2 2022, down 11.06% sequentially from $12.2 million in Q1 2022.
Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends
Edgewise Therapeutics has reported Total Non-Current Liabilities for 2 years, with the latest figure at $10.9 million in Q2 2022.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $10.9 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $10.9 million (changed N/A YoY) and the FY2021 annual result came in at $10.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $10.9 million in Q2 2022 per EWTX's latest filing, from $12.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $12.2 million in Q1 2022 and troughed at $8.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 10.85 Mn |
| Mar 31, 2022 | 12.20 Mn |
| Dec 31, 2021 | 10.52 Mn |
| Sep 30, 2021 | 8.75 Mn |